Skip to main content
HBIO
NASDAQ Industrial Applications And Services

Harvard Bioscience Reports Strong Preliminary Q4 Results, Outlines Growth Strategy for 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.54
Mkt Cap
$23.706M
52W Low
$0.281
52W High
$1.522
52W Position info
92% above low
Off High info
65% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

HBIO sits 92% above its 52-week low of $0.281 on light trading volume (0.2× avg).

Summary

Harvard Bioscience announced preliminary Q4 2025 financial results exceeding guidance and unveiled a long-term strategic plan focused on translational science, new product innovation, and operational excellence, projecting revenue and EBITDA growth for 2026.


Key Events · Earnings and Guidance · HBIO

  • Preliminary Q4 2025 Financial Performance

    Reported preliminary Q4 2025 revenue of $23.7 million, above the midpoint of guidance, with a gross margin of 60% (high end of guidance) and 27% year-over-year adjusted EBITDA growth to $3.8 million.

  • Positive 2026 Outlook

    Management expects year-over-year revenue growth and mid-to high-single-digit adjusted EBITDA growth for 2026.

  • New Long-Term Strategic Plan Unveiled

    The company outlined a cohesive long-term strategy to become a leader in translational science tools, focusing on new product introduction, consumables revenue expansion, and operational excellence.

  • Operational Improvements Highlighted

    The strategy builds on recent debt refinancing and the previously announced U.S. manufacturing consolidation (Project Viking), aiming for consistent profitability and a stronger balance sheet.


Analysis · HBIO · Industrial Applications And Services

This 8-K provides a crucial positive update for Harvard Bioscience, coming after a series of recent filings indicating financial challenges such as a proposed reverse stock split and a significant dilutive resale offering. The preliminary Q4 2025 results show performance at or above guidance, with strong EBITDA growth, suggesting operational improvements are taking hold. The outlined long-term strategy, focusing on high-growth areas like translational science and expanding recurring revenue, coupled with a positive 2026 outlook, aims to reassure investors and provide a clear path to sustainable growth and improved shareholder value. This filing attempts to shift the narrative from recent concerns to a more optimistic future.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HBIO was trading at $0.54 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $23.7M. The 52-week trading range was $0.28 to $1.52. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HBIO - Latest Insights

HBIO
Nov 10, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.26
Real-time Price: $9.39 info
Change: +$0.130 (+1%) info
Market Cap: $42.941M info
HBIO
Nov 10, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.09
Real-time Price: $9.39 info
Change: +$0.300 (+3%) info
Market Cap: $42.941M info
HBIO
Nov 10, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.09
Real-time Price: $9.39 info
Change: +$0.300 (+3%) info
Market Cap: $42.941M info
HBIO
Nov 10, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $9.09
Real-time Price: $9.39 info
Change: +$0.300 (+3%) info
Market Cap: $42.941M info
HBIO
Aug 11, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.13
Real-time Price: $9.39 info
Change: +$3.26 (+53%) info
Market Cap: $42.941M info